GlaxoSmithKline Biologicals SA
8,371.0 FTEGlaxoSmithKline Biologicals reported revenue of €7.44bn for the 2025 financial year (non-consolidated annual accounts filed with the NBB on 30 Jun 2026), with 8,371 full-time equivalents.
By total assets for 2025, GlaxoSmithKline Biologicals ranks among the 3 largest of the 173 companies in its sector (NACE 2120) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of GlaxoSmithKline Biologicals shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +4 % Equity -32 % Total assets +3 % Headcount (avg FTE) -2 %
Accounts of the company itself (not consolidated). Consolidated group accounts are also filed: they are in the full file.
The full file covers 13 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
GlaxoSmithKline Biologicals's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €7.44bn | ||||
| Net result | €2.40bn | ||||
| Equity | €9.98bn | ||||
| Cash | 21,733 € | ||||
| EBITDA | €4.46bn | ||||
| Total assets | €17.8bn |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jun 2026
- Year ended 31 Dec 2024filed on 02 Jul 2025
- Year ended 31 Dec 2023filed on 29 Jul 2024
- Year ended 31 Dec 2022filed on 06 Jul 2023
- Year ended 31 Dec 2021filed on 20 Jul 2022
GlaxoSmithKline Biologicals's financial analysis
- Solvency55.9%sector median: 34.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of GlaxoSmithKline Biologicals
9 active director(s) in the register.
and 3 more
GlaxoSmithKline Biologicals's shareholders and holdings →GlaxoSmithKline Biologicals's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0440.872.918
- VAT number
- BE0440872918
- Peppol
- Registered · 0208:0440872918 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 01 Jul 1990
- Registered office
- 1330 Rixensart
- Size
- Large · 8,371.0 FTE
- Latest accounts
- 2025 · filed on 30 Jun 2026
- Activity
- Manufacture of medicaments (NACE 21201)
GlaxoSmithKline Biologicals (SA) has been based in Rixensart since 1990, active in: manufacture of medicaments. For 2025, it reports revenue of €7.44bn, a net profit of €2.40bn and equity of €9.98bn. With 8,371.0 full-time equivalents, it is a large enterprise by headcount. Its solvency stands at 55.9%, above the median of its sector (34.4%).
Guide: Checking a Belgian supplier invoice: numbers and IBAN →
Companies similar to GlaxoSmithKline Biologicals
Companies in the same business, of comparable size and area, outside its group.
- Pfizer Manufacturing Belgium Manufacture of pharmaceutical preparations Puurs-Sint-Amands · balance sheet €2.46bn
- Genzyme Flanders Manufacture of pharmaceutical preparations Geel · balance sheet €1.00bn
- Baxalta Belgium Manufacturing Manufacture of basic pharmaceutical products Lessines · balance sheet €713.1m
- Laboratoires S.M.B. Manufacture of pharmaceutical preparations Molenbeek-Saint-Jean · balance sheet €261.5m
- Baxter Manufacture of pharmaceutical preparations Lessines · balance sheet €160.0m
- Novartis Manufacturing Manufacture of pharmaceutical preparations Puurs-Sint-Amands · balance sheet €285.2m
- Novo Nordisk Production Belgium SA Manufacture of pharmaceutical preparations Brussels · balance sheet €153.5m
- Odyssea Pharma Manufacture of pharmaceutical preparations Grâce-Hollogne · balance sheet €91.0m
Frequently asked questions about GlaxoSmithKline Biologicals
What is the revenue of GlaxoSmithKline Biologicals?
According to the 2025 annual accounts filed with the NBB, the revenue of GlaxoSmithKline Biologicals amounts to 7,439,791,208 €.
What is the VAT number of GlaxoSmithKline Biologicals?
In Belgium, the VAT number is the company number prefixed with BE: BE0440872918 for GlaxoSmithKline Biologicals, if the company is VAT-registered. Its company number (CBE) is 0440.872.918.
Where is the registered office of GlaxoSmithKline Biologicals?
According to the CBE register, the registered office of GlaxoSmithKline Biologicals is in 1330 Rixensart.
What is the equity of GlaxoSmithKline Biologicals?
At the close of the 2025 financial year, the equity of GlaxoSmithKline Biologicals amounts to 9,976,136,779 €, a solvency of 55.9% of total assets.
How many people work at GlaxoSmithKline Biologicals?
8,371.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages GlaxoSmithKline Biologicals?
The register lists 9 active mandates at GlaxoSmithKline Biologicals. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is GlaxoSmithKline Biologicals within its sector?
By total assets for 2025, GlaxoSmithKline Biologicals ranks among the 3 largest of the 173 companies in its sector (NACE 2120) in Belgium that filed accounts for that financial year.
The full file of GlaxoSmithKline Biologicals
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →